13512
Blog
Laci Costa

Real World Clinical Performance of Aidoc’s Vessel Occlusion Algorithm vs. Conventional AI

Anterior LVO, Care Coordination, MeVO, Stroke
Table of Contents

AI is increasingly being used to assist in prioritizing suspected stroke cases, but not all AI solutions are created equal. While the overarching clinical goals may be similar, significant variability exists in how these technologies perform. 

These performance differences directly impact crucial factors such as algorithm accuracy, user experience , patient outcomes and return on investment (ROI). Understanding the distinctions between AI solutions is essential for stroke care teams to make informed choices that ultimately influence life-changing patient care.

New Data Compares Aidoc’s Performance with Another Conventional AI Solution

A recent study from Atlantic Health System was presented at this year’s ASNR. It compared Aidoc’s Full Brain AI Solution for prioritizing suspected vessel occlusions (VOs) in stroke code patients using head CTA scans against another conventional AI solution.

While we’re proud of the results, we’re also not surprised: Aidoc outperformed the other conventional solution in sensitivity, specificity and positive predictive value (PPV).1

The aiOS™ Makes it All Possible

All of Aidoc’s algorithms are run on the proprietary aiOS™ platform. Using intelligent orchestration, aiOS™ can identify anatomy on scans and run all relevant algorithms to flag both expected and unexpected conditions to enable better prioritization. Plus, Aidoc is the only healthcare AI company with FDA clearance to flag both large and medium vessel occlusions in the anterior and posterior circulation.

This data demonstrates Aidoc’s ability to help stroke care teams:

  • Flag expected and unexpected VOs
  • Make treatment decisions faster
  • Expedite time-to-treatment through workflow optimization
  • Improve standard of care for patients

Get the infographic to view and share the data.

  1. Head-to-Head Comparison of Two AI Software Solutions for Detecting Vessel Occlusions in Stroke Code Patients Using Head and Neck CTA Scans. Han Zhong MD1, Christopher Ciasullo DO1, Kevin Pham DO2, Devon Klein MD, Overlook Medical Center, Summit, NJ, USA.


Note: the research is describing investigational use of the device. For safety information on Aidoc’s products, please visit our safety and compliance page.

Explore the Latest AI Insights, Trends and Research

Follow a manual added link

Webinars

Aidoc experts, customers and industry leaders share the latest in AI benefits and adoption.

Follow a manual added link

eBooks

Explore how clinical AI can transform your health system with insights rooted in real-world experiences.

Follow a manual added link

AI Strategy

Learn how to go beyond the algorithm to develop a scalable AI strategy and implementation plan.

Follow a manual added link

Solutions

Explore how Aidoc can help increase hospital efficiency, improve outcomes and demonstrate ROI.

Laci Costa
Laci Costa is the Director of Neurovascular Product Marketing at Aidoc. She leads marketing and commercial strategy for the neuro AI portfolio of products. She has 16 years of experience working in the medical device and healthcare industry, with over 12 years dedicated to neurovascular solutions. Costa's known for her expertise in the neurovascular industry, go-to-market experience with new technologies and upstream and downstream product marketing leadership. She's held various leadership positions in product marketing, clinical education and professional affairs spanning across start-up organizations to large publicly traded companies. Costa holds a bachelor’s degree in psychology from the University of Oklahoma and an MBA from USC Marshall School of Business.
Laci Costa
Director, Neurovascular Product Marketing

© Copyright 2025 Aidoc